Skip to main content
Premium Trial:

Request an Annual Quote

Deal for Home Testing

The Biden Administration has reached a $231 million deal with Ellume for its rapid, at-home, over-the-counter test for SARS-CoV-2, as 360Dx reports.

The Australian-based Ellume received an Emergency Use Authorization for its rapid, lateral flow antigen test in December. The test further connects to a smartphone app to deliver results. At the time, the US Food and Drug Administration said the test identified 96 percent of positive samples and all negative samples from symptomatic individuals and 91 percent of positive samples and 96 percent of negative samples from asymptomatic individuals.

With this new contract, the Department of Defense is to help Ellume build a US manufacturing plant with the capability of producing 500,000 tests per day and Ellume is to provide the US federal government with 8.5 million tests, NPR reports. It adds that the first tests provided will be manufactured at the company's Australian facility. 

Harvard University's Michael Mina tells NBC News that the effort is "a step forward in giving Americans access to at-home rapid testing," but adds that "for us to stop the spread of the virus, we need to scale cheap and simple paper-strip antigen tests that a majority of Americans can afford to use frequently."

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.